No, the gist was withholding information from shareholders that the FDA wanted another trial for approval to allow shareholders to make informed decisions. The FDA did knock it back for this reason on first and second attempt, consistent with what the privaledged insiders knew. A lot of investors made larger investments than they would have had they known the full story. That's why some may still be under water even after approval. Not everyone was in a position to average down.
MSB Price at posting:
$3.19 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)